Compare UFG & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | SNTI |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | Singapore | United States |
| Employees | 17 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 29.8M |
| IPO Year | N/A | 2021 |
| Metric | UFG | SNTI |
|---|---|---|
| Price | $0.67 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 153.0K | ★ 181.8K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.60 | $0.77 |
| 52 Week High | $9.91 | $3.88 |
| Indicator | UFG | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 47.55 |
| Support Level | $0.63 | $0.86 |
| Resistance Level | $1.02 | $1.02 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 26.52 | 40.88 |
Uni-Fuels Holdings Ltd is a service provider of marine fuels solutions. The company market, resell and brokers marine fuels products such as VLSFO, HSFO, and MGO. It offers these products to shipping companies and marine fuels suppliers in-port and offshore. In addition, the company may from time to time provide shipping-related services to its customers including but not limited to the arrangement of ship agents, ship provisions and marine fuels surveyors. It operates an integrated business model where It serves its customers through two operating models, sales of marine fuels solutions and brokerage.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).